SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Telegram Restored on Apple App Store After Temporary Removal 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
 for treatment of cutaneous T-cell lymphoma (CTCL) - EconoTimes)
La Chaux-de-Fonds, Switzerland, April 09, 2018 -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the active moiety of Tenalisib (RP6530), the Company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for treatment of cutaneous T-cell lymphoma (CTCL).
“We are pleased to receive US FDA orphan-drug designations for the active moiety of Tenalisib (RP6530) for the treatment of peripheral and cutaneous T-cell Lymphoma (PTCL and CTCL), and we look forward to advancing the drug into further development for treatment of T-cell lymphoma,” said Swaroop Vakkalanka, Ph.D., Founder & President of Rhizen Pharmaceuticals S.A.
About FDA Orphan-Drug Designation:
Orphan-Drug Designation is granted to a drug or biological product intended to treat a rare disease in the United States. A number of incentives are provided for an orphan-drug such as 7-year marketing exclusivity, tax credits for clinical development costs, exemption/waiver of application (filing) fees and assistance from the FDA Office of Orphan Products Development (OOPD) during the development process.
About Tenalisib (RP6530):
Tenalisib (RP6530) is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies. Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of tumor microenvironment at clinically achievable concentrations. In preclinical studies, RP6530 reprograms macrophages from an immunosuppressive M2-like phenotype (pro-tumor) to an inflammatory M1-like state (anti-tumor), which can potentially enhance the activity of checkpoint inhibitors or overcome resistance to these drugs. Tenalisib obtained US FDA Fast Track Designation for treatment of peripheral T-cell lymphoma (PTCL) in addition to Orphan-Drug Designations for treatment of peripheral and cutaneous T-cell lymphoma (PTCL and CTCL).
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.
Contact: Kumar V. Penmetsa, Ph.D. Executive Vice President, Corporate Development Rhizen Pharmaceuticals S.A. Telephone: +1-267-207-5707 Email: [email protected]
